Obagi Nu-Cil Lash Serum Review

Brand & Product Overview

Obagi Medical is a US physician-skincare brand with established credibility in dermatology and medical aesthetics, best known for its prescription-grade Obagi Nu-Derm and Blue Peel protocols. The Obagi Nu-Cil Eyelash Enhancing Serum is their lash growth serum, primarily sold through dermatologist offices, medical spas, and authorised skincare distributors like Dermstore and Skinstore. It is also available on Amazon (ASIN B09C82MWZX).

$67.99–$120 / 3 mL = ~$22.66–40 per mL · Physician-distribution tier

Obagi developed Nu-Cil as a physician-recommended alternative to Latisse (bimatoprost), using Dehydrolatanoprost — a different prostaglandin analogue from the latanoprost family — to activate lash growth through the same FP receptor pathway. The NouriPlex Technology (Biotin + Panthenol + HA) supports conditioning alongside the prostaglandin active.

Dehydrolatanoprost: What It Is and How It Works

Dehydrolatanoprost is a synthetic prodrug that, when applied topically, converts to latanoprost — the active FP receptor agonist used as an FDA-approved ophthalmic drug for glaucoma (under the brand Xalatan, among others). The "dehydro" prefix indicates a structural modification that improves topical skin penetration and corneal permeation compared to latanoprost itself.

Mechanism of Action

Like all prostaglandin FP agonists (bimatoprost, latanoprost, ICP, DDDE), Dehydrolatanoprost activates the FP prostaglandin receptor in the hair follicle. FP receptor activation extends the anagen (active growth) phase, increases the number of lash follicles in anagen simultaneously, and slightly increases the diameter of the hair matrix. This is the same fundamental mechanism as Latisse (bimatoprost), working at the same receptor but through a cosmetic rather than pharmaceutical-grade product.

Why Physician Distribution Matters — and Its Limits

Obagi's decision to sell Nu-Cil primarily through physician offices reflects an attempt to provide appropriate clinical oversight for a prostaglandin-containing product. Physicians can monitor for side effects, assess individual risk (particularly for glaucoma patients on FP agonist eye drops), and advise on appropriate use.

However, Nu-Cil is also available on Amazon and through general skincare retailers without clinical oversight. Consumers purchasing online receive no physician guidance on risk assessment, contraindications, or monitoring.

Full Ingredient Analysis (12 INCI)

Dehydrolatanoprost at position 2 — immediately after water — indicates it is at a relatively high concentration compared to ICP in many competitor formulas where it appears lower in the INCI. This is consistent with Obagi's physician-oriented formulation approach (likely optimised for clinical efficacy within the intended use parameters).

Phenethyl Caffeate (CAPE) — the "proprietary lipid compound" in NouriPlex — is an interesting addition. CAPE is the active ester found in bee propolis, with well-documented antioxidant and anti-inflammatory properties. Preliminary research suggests weak 5-alpha reductase inhibiting properties. Unusual but genuine addition at the low concentration its INCI position implies.

Clinical Evidence

Obagi's brand-sponsored 16-week clinical study (conducted with physician oversight at aesthetic medicine centres) reported:

• 93% of participants reported visible improvement in eyelash appearance
• 89% reported lashes looking thicker
• 89% reported lashes appearing denser

The 16-week study duration is the longest of any brand clinical data reviewed in this series. The prostaglandin mechanism of Dehydrolatanoprost is well-validated in ophthalmology (latanoprost for glaucoma has decades of evidence), so the efficacy claim is pharmacologically credible. However, the study is brand-commissioned and not independently audited.

Side Effects

Because Obagi Nu-Cil contains Dehydrolatanoprost — an FP receptor agonist — it shares the prostaglandin class side-effect profile documented across bimatoprost (Latisse), ICP (GrandeLASH, RapidLash, etc.), and other FP agonists:

• Iris pigmentation — Permanent darkening of blue, green, or hazel eyes through FP receptor-mediated melanogenesis.
• Periorbital fat atrophy — Reduction of orbital fat via FP receptor lipolysis — sunken eye appearance.
• Eyelid hyperpigmentation — Darkening at the lash line skin.
• Upper eyelid sulcus deepening — Upper lid contour change from fat volume loss.
• Ocular irritation — Burning, redness, tearing, sensitivity.
• Glaucoma drug interference — FP receptor cross-reactivity with latanoprost, bimatoprost, travoprost glaucoma medications.

Obagi's website acknowledges these class risks, consistent with the physician-distribution model that enables patient counselling. For consumers purchasing through general retail channels, this oversight is absent.

Obagi Nu-Cil vs. Toplash: Full Comparison

Frequently Asked Questions